Pliant Therapeutics, Inc. (PLRX)

Market Cap	774.67M
Revenue (ttm)	n/a
Net Income (ttm)	-201.68M
Shares Out	60.85M
EPS (ttm)	-3.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	468,630
Open	12.67
Previous Close	12.79
Day's Range	12.22 - 12.74
52-Week Range	10.22 - 19.62
Beta	1.09
Analysts	Strong Buy
Price Target	40.50 (+218.15%)
Earnings Date	Nov 7, 2024

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Financial Performance

In 2023, Pliant Therapeutics's revenue was $1.58 million, a decrease of -83.69% compared to the previous year's $9.69 million. Losses were -$161.34 million, 30.8% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for PLRX stock is "Strong Buy." The 12-month stock price forecast is $40.5, which is an increase of 218.15% from the latest price.

Price Target

$40.5

(218.15% upside)

Analyst Consensus: Strong Buy